Supplementary Figure 13 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Year: 2024
Type: supplementary-materials
Abstract: Increase in both ctDNA metrics identifies a subgroup with particularly poor outcome. Post-hoc analysis of ΔCSM and ΔCMC together demonstrates that a decrease in either metric was sufficient to result in significantly improved PFS and OS, whereas increase in both metrics identified a group with particularly poor outcomes. PFS analysis at cycle 3 excludes one patient who progressed before the collection of cycle 3 sample.
Authors: Eric Y. Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui (Amy) Liu, Derek Wong, Kayla Marsh, Albiruni R. Abdul Razak, Anna Spreafico, Philippe L. Bedard, Aaron R. Hansen, Stephanie Lheureux, Dax Torti, Bernard Lam, Shih Yu Cindy Yang, Justin Burgener, Ping Luo, Yong Zeng, Nicholas Cheng, Philip Awadalla, Scott V. Bratman, Pamela S. Ohashi, Trevor J. Pugh, Lillian L. Siu
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4399299474